Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs

Cancer Letters

Volumn 236, Issue 1, 2006, Pages 95-104

  Fuessel, Susanne ^a   Weigle, Bernd ^a   Schmidt, Uta ^a   Baretton, Gustavo ^a   Koch, Rainer ^a   Bachmann, Michael ^a   Rieber, E Peter ^a   Wirth, Manfred P ^a   Meye, Axel ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Expression profile; G protein coupled receptor; LightCycler; Prostate cancer; Quantitative real time PCR

Indexed keywords

DRESDEN G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC;

AGED; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33646109808     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.05.005     Document Type: Article

References (34)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
2. Barry M.J., Albertsen P.C., Bagshaw M.A., Blute M.L., Cox R., Middleton R.G., et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 91 (2001) 2302-2314
3. Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J. Clin. Oncol. 20 (2002) 3972-3982
4. Rosenberg J., and Small E.J. Prostate cancer update. Curr. Opin. Oncol. 15 (2003) 217-221
5. Harada M., Noguchi M., and Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int. J. Clin. Oncol. 8 (2003) 193-199
6. Weigle B., Fuessel S., Ebner R., Temme A., Schmitz M., Schwind S., et al. D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem. Biophys. Res. Commun. 322 (2004) 239-249
7. Xu L.L., Stackhouse B.G., Florence K., Zhang W., Shanmugam N., Sesterhenn I.A., et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res. 60 (2000) 6568-6572
8. Xia C., Ma W., Wang F., Hua S., and Liu M. Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene 20 (2001) 5903-5907
9. Yuan T.T., Toy P., McClary J.A., Lin R.J., Miyamoto N.G., and Kretschmer P.J. Cloning and genetic characterization of an evolutionarily conserved human olfactory receptor that is differentially expressed across species. Gene 278 (2001) 41-51
10. Edwards S.W., Tan C.M., and Limbird L.E. Localization of G-protein-coupled receptors in health and disease. Trends Pharmacol. Sci. 21 (2000) 304-308
11. Liebmann C. G protein-coupled receptors and their signaling pathways: classical therapeutical targets susceptible to novel therapeutic concepts. Curr. Pharm. Des. 10 (2004) 1937-1958
12. Kranenburg O., and Moolenaar W.H. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 20 (2001) 1540-1546
13. Whitehead I.P., Zohn I.E., and Channing J.D. Rho GTPase-dependent transformation by G protein-coupled receptors. Oncogene 20 (2001) 1547-1555
14. Julius D., Livelli T.J., Jessell T.M., and Axel R. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 244 (1989) 1057-1062
15. Allen L.F., Lefkowitz R.J., Caron M.G., and Cotecchia S. G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc. Natl. Acad. Sci. USA 88 (1991) 11354-11358
16. Gutkind J.S., Novotny E.A., Brann M.R., and Robbins K.C. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc. Natl. Acad. Sci. USA 88 (1991) 4703-4707
17. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
18. Raj G.V., Barki-Harrington L., Kue P.F., and Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J. Urol. 167 (2002) 1458-1463
19. Bookout A.L., Finney A.E., Guo R., Peppel K., Koch W.J., and Daaka Y. Targeting Gbetagamma signaling to inhibit prostate tumor formation and growth. J. Biol. Chem. 278 (2003) 37569-37573
20. Nelson J.B., Hedican S.P., George D.J., Reddi A.H., Piantadosi S., Eisenberger M.A., et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1 (1995) 944-949
21. Opgenorth T.J., Adler A.L., Calzadilla S.V., Chiou W.J., Dayton B.D., Dixon D.B., et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276 (1996) 473-481
22. Carducci M.A., Padley R.J., Breul J., Vogelzang N.J., Zonnenberg B.A., Daliani D.D., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J. Clin. Oncol. 21 (2003) 679-689
23. Weigle B., Kiessling A., Ebner R., Fuessel S., Temme A., Meye A., et al. D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer. Int. J. Cancer 109 (2004) 882-892
24. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., and Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61 (2001) 3550-3555
25. Fussel S., Sickert D., Meye A., Klenk U., Schmidt U., Schmitz M., et al. Multiple tumour marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int. J. Oncol. (2003) 21-29
26. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother. Rep. 50 (1966) 125-128
27. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 23 (1992) 273-279
28. DeLong R., DeLong D., and Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
29. Gjengsto P., Paus E., Halvorsen O.J., Eide J., Akslen L.A., Wentzel-Larsen T., et al. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. J. Urol. 173 (2005) 425-428
30. Ozdal O.L., Aprikian A.G., Begin L.R., Behlouli H., and Tanguay S. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. BJU Int. 93 (2004) 970-974
31. McArdle P.A., Pollock M.A., Wallace A.M., McMillan D.C., Crooks J.E., and Underwood M.A. Comparison of total, complexed and free prostate-specific antigens and their ratios in the detection of prostate cancer in a non-screened population. Ann. Clin. Biochem. 41 (2004) 201-206
32. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62 (2002) 2695-2698
33. Landers K.A., Burger M.J., Tebay M.A., Purdie D.M., Scells B., Samaratunga H., et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int. J. Cancer 114 (2005) 950-956
34. Weng J., Wang J., Cai Y., Stafford L.J., Mitchell D., Ittmann M., et al. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int. J. Cancer 113 (2005) 811-818